Innovative therapies in myeloid leukemias (INOVTEAM)

The lysosome is a key organelle for the uptake and degradation of proteins through a spectrum of processes such as Macroautophagy and Chaperone-mediated Autophagy (CMA). In our research we have highlighted the importance of this organelle during aging and its importance in the genesis of myeloid leukemias. We are currently studying the impact of the invalidation of a lysosomal protein on the deregulation of the hematopoietic compartment and the genesis of myeloid leukemias, using original mouse models.

Cellular Reprogramming

My group focus on the study of myeloid immunosuppressive cells, such as anti-inflammatory macrophages (Leukemia-Associated Macrophages and TAMs) and MDSCs (Myeloid-derived suppressor cells), in hematopoietic malignancies (AML, MDS and CMML). The main function of these cells in cancer is to inhibit the antitumor immune response. Therefore, understanding the molecular mechanisms involved in the generation of LAMs and MDSCs might provide an opportunity for the design of novel therapeutic strategies. A better characterization of their origin, phenotype and ability to trigger an antitumor response and how these different myeloid immunosuppressive subpopulations could be impacted by anticancer therapies is urgently needed to selectively target/reprogram them in different types of leukemia.